Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 1, 1997, Pages 49-56

  Smits, Glenn J ^a,b   Perrone, Mark H ^a   Cox, Bryan F ^a  

^a Cardiovascular Biology   (United States)

^b DEBORAH HEART AND LUNG CENTER   (United States)

Author keywords

Glybenclamide; Hemodynamic profile; Lemakalim

Indexed keywords

GLIBENCLAMIDE; LEMAKALIM; PINACIDIL; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANESTHESIA; ANIMALS; BENZOPYRANS; BLOOD CIRCULATION; BLOOD PRESSURE; CORONARY CIRCULATION; CROMAKALIM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYBURIDE; HINDLIMB; MALE; POTASSIUM CHANNELS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE;

EID: 0031030194     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199701000-00008     Document Type: Article

References (21)

1. Cavero I, Mondot S, Mestre M. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels. J Pharmacol Exp Ther 1989;248(3):1261-8.
2. Hof RP, Quast U, Cook NS, Blarer S. Mechanism of action and systemic and regional hemodynamics of the potassium channel activator BRL34915 and its enantiomers. Circ Res 1988;62:679-86.
3. ATP channel opener, lemakalim, on systemic, coronary and regional vascular dynamics in conscious dogs: comparison with nifedipine, adenosine, nitroglycerin and acetylcholine. J Pharmacol Exp Ther 1993;265(2):1026-37.
4. Uchida W, Masuda N, Taguchi T, et al. Pharmacologic profiles of YM934, a novel potassium channel opener. J Cardiovasc Pharmacol 1994;23:180-7.
5. Clapham JC, Hamilton TC, Longman SD, et al. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models. Arzneimforschung/ Drug Res 1991;41(I):385-91.
6. + channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats. J Pharmacol Exp Ther 1991;258:216-22.
7. + channel opener aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther 1991;259(3):961-7.
8. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.
9. Grover GJ, Dzwonczyk S, Sleph PG. Reduction of ischemic damage in isolated rat hearts by the potassium channel opener, RP 52891. Eur J Pharmacol 1990;191:11-8.
10. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74(5):1124-36.
11. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.
12. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart. Am J Physiol 1992;263:H1107-12.
13. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-23.
14. Moreau R, Komeichi H, Kirstetter P, et al. Effects of glibenclamide on systemic and splanchnic haemodynamics in conscious rats. Br J Pharmacol 1994;112:649-53.
15. Post JM, Stevens RJ, Sanders KM, Hume JR. Effects of cromakalim and lemakalim on slow waves and membrane currents in colonie smooth muscle. Am J Physiol 1991;260:C375-82.
16. Haywood JR, Shaffer RA, Fastenow W, Fink GD, Brody MJ. Regional blood flow measurement in the conscious rat with a pulsed Doppler flow meter. Am J Physiol 1981;241:20.
17. Longman SD, Clapham JC, Wilson C, Hamilton TC. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil. J Cardiovasc Pharmacol 1988;12:535-42.
18. Yamada H, Yoneyama F, Satoh K, Taira N. Specific but differential antagonism by glybenclamide of the vasodepressor effects of cromakalim and nicorandil in spinally-anesthetized dogs. Br J Pharmacol 1990;100:413-6.
19. Lu H, Remeysen P, DeClerk F. The protection by ischemic preconditioning against myocardial ischemia- and reperfusion-induced arrhythmias is not mediated by ATP-sensitive potassium channels in rats. Coron Artery Dis 1993;4(7):649-57.
20. Fralix TA, Steenbergen C, London RE, Murphy E. Glibenclamide does not abolish the protective effect of preconditioning in stunning in the isolated perfused rat heart. Cardiovasc Res 1993;27(4):630-7.
21. Grover GJ, Dzwonczyk S, Sleph PG, Sargent CA. The ATP-dependent potassium channel blocker glybenclamide (glybunde) does not abolish preconditioning in isolated ischemic rat hearts. J Pharmacol Exp Ther 1993;265(2):559-64, H273-8.